Oracle Adds Healthcare Software Maker Phase Forward

Oracle has said it will shell out $685 million to acquire Phase Forward, an on-demand provider of drug data management and health science software. The all-cash transaction, which values Phase Forward (NASDAQ: PFWD) at about 30 percent above its closing price Thursday, is just the latest salvo in Oracle’s (NASDAQ: ORCL) decade-long blood war with […]

Written By
Larry Barrett
Larry Barrett
Published: Apr 19, 2010
Updated: Jan 28, 2021
3 minute read
Datamation content and product recommendations are editorially independent. We may make money when you click on links to our partners. Learn More





Oracle has said it will shell out $685 million to acquire Phase Forward, an on-demand provider of drug data management and health science software.

The all-cash transaction, which values Phase Forward (NASDAQ: PFWD) at about 30 percent above its closing price Thursday, is just the latest salvo in Oracle’s (NASDAQ: ORCL) decade-long blood war with archenemy SAP.

Oracle will buy the Waltham, Mass.-based company for $17 a share and fold Phase Forward’s employees and management team into its Health Sciences global business unit, it said.

By picking up one of the leading providers of applications used to manage clinical research studies and drug development, Oracle’s new unit will make it a more attractive option to hospitals, universities and private research labs in the highly lucrative healthcare and life science verticals.

Oracle has ratcheted up the pressure on SAP, IBM (NYSE: IBM) and Microsoft (NASDAQ: MSFT) in recent years by paying healthy premiums to acquire software companies that specialize in applicationsused for key vertical such as telecom, financial services, energy and healthcare.

“The life sciences and healthcare industries are converging as they seek to control costs while accelerating patient-centered innovation,” Neil de Crescenzo, general manager of Oracle’s Health Sciences unit, said in a statement. “Phase Forward brings outstanding products and employees with significant expertise to Oracle that will help enable the delivery of personalized medicine and value-based healthcare.”

No stranger to acquisitions, the Phase Forward deal marks Oracle’s 55th acquisition since 2005. In February, it added Convergin, an Israel-based developer of real-time service brokering applications for the telecom industry. Also that month, it snapped up SOA management software maker AmberPoint.

Oracle officials said the company plans to close the Phase Forward deal sometime near the middle of this year, assuming the purchase clears the customary reviews by regulators.

Larry Barrett is a senior editor at InternetNews.com, the news service of Internet.com, the network for technology professionals.

Advertisement

  SEE ALL
APPLICATIONS ARTICLES
 

Larry Barrett

Larry Barrett

Content Writer

Larry was a senior writer and editor at CNet, writing analysis, breaking news and opinion stories. He was technology reporter at the San Jose Business Journal from 1996-1997.

Datamation Logo

Datamation is the leading industry resource for B2B data professionals and technology buyers. Datamation's focus is on providing insight into the latest trends and innovation in AI, data security, big data, and more, along with in-depth product recommendations and comparisons. More than 1.7M users gain insight and guidance from Datamation every year.

Property of TechnologyAdvice. © 2026 TechnologyAdvice. All Rights Reserved

Advertiser Disclosure: Some of the products that appear on this site are from companies from which TechnologyAdvice receives compensation. This compensation may impact how and where products appear on this site including, for example, the order in which they appear. TechnologyAdvice does not include all companies or all types of products available in the marketplace.